The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade

The oncolytic peptide LTX-315 triggers immunogenic cell death

(2016) H Zhou et al.   Cell Death & Disease

A Threshold Level of Intratumor CD8 + T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1

(2015) Shin Foong Ngiow et al.   CANCER RESEARCH

The oncolytic peptide LTX-315 triggers necrotic cell death

(2015) Sabrina Forveille et al.   CELL CYCLE

Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25

(2015) Dalil Hannani et al.   CELL RESEARCH

Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1–derived oncolytic immunotherapy

(2015) Kevin J Harrington et al.   Expert Review of Anticancer Therapy

Tumor Microenvironment and Immunotherapy: The Whole Picture Is Better Than a Glimpse

(2015) Sarah E. Church et al.   IMMUNITY

Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy

(2015) A. Sivan et al.   SCIENCE

Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1

(2015) E. Vacchelli et al.   SCIENCE

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

(2015) M. Vetizou et al.   SCIENCE

The oncolytic peptide LTX-315 kills cancer cells through Bax/Bak-regulated mitochondrial membrane permeabilization

(2015) Heng Zhou et al.   Oncotarget

Microbiota of Human Breast Tissue

(2014) Camilla Urbaniak et al.   APPLIED AND ENVIRONMENTAL MICROBIOLOGY

Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315

(2014) Ketil André Camilio et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Intratumoral Immunization: A New Paradigm for Cancer Therapy

(2014) A. Marabelle et al.   CLINICAL CANCER RESEARCH

Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

(2014) Antonella Sistigu et al.   NATURE MEDICINE

LTX-315 (Oncopore™)

(2014) Ketil André Camilio et al.   OncoImmunology

Low-Dose Irradiation Programs Macrophage Differentiation to an iNOS+/M1 Phenotype that Orchestrates Effective T Cell Immunotherapy

(2013) Felix Klug et al.   CANCER CELL

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors

(2013) Aurélien Marabelle et al.   JOURNAL OF CLINICAL INVESTIGATION

Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment

(2013) N. Iida et al.   SCIENCE

The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide

(2013) S. Viaud et al.   SCIENCE

Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells

(2013) M. J. Selby et al.   Cancer Immunology Research

Regulation of multiple DNA repair pathways by the Fanconi anemia protein SLX4

(2012) Y. Kim et al.   BLOOD

Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma

(2012) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Structural Studies of a Peptide with Immune Modulating and Direct Antimicrobial Activity

(2010) Michal Wieczorek et al.   CHEMISTRY & BIOLOGY

In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study

(2010) Joshua D. Brody et al.   JOURNAL OF CLINICAL ONCOLOGY

Cationic amphiphilic peptides with cancer-selective toxicity

(2009) Frank Schweizer   EUROPEAN JOURNAL OF PHARMACOLOGY

CD4+CD25+ Tregs control the TRAIL-dependent cytotoxicity of tumor-infiltrating DCs in rodent models of colon cancer

(2008) Stephan Roux et al.   JOURNAL OF CLINICAL INVESTIGATION

Studies on anticancer activities of antimicrobial peptides

(2007) David W. Hoskin et al.   BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES